Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Local Medicare Coding Will Be Eliminated In Two Years Under Final Rule

This article was originally published in The Gray Sheet

Executive Summary

HCFA's Aug. 17 final rule implementing standards for electronic transactions requires local Medicare contractors to process all services for which they receive fewer than 50 claims annually under an unlisted, or "Not Otherwise Specified," code.

You may also be interested in...



Further BBA Relief Legislation To Be Marked Up By Mid-September

AdvaMed is working to ensure that portions of the Medicare Patient Access to Technology Act (HR 4395) will be incorporated into balanced budget act relief legislation by the time it is marked up in mid-September.

Medicare Delays Extend Time To Profitability For Device Firms - Lewin Group

Small device manufacturers that encounter a two-year delay in obtaining appropriate Medicare reimbursement must raise double the amount of capital in order to become profitable, according to a report released Aug. 7 by the Lewin Group.

Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use

The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip

Latest Headlines
See All
UsernamePublicRestriction

Register

MT013786

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel